News

OM is a radio/chemotherapy related condition and it occurs frequently in patients undergoing head and neck cancer treatment. This condition is considered as ‘non severe’ for grades 0

The trial named AIM-TD (Addressing Involuntary Movements in Tardive Dyskinesia) is the company’s second pivotal clinical trial to assess SD-809 in tardive dyskinesia patients. The company intends to

Incruse is a long-acting muscarinic antagonist (LAMA), a type of bronchodilator which can relax airway muscles and improve airflow in and out of the lungs. Umeclidinium is the

The contract expansion will include the production of commercial quantities of a second BMS biologic medicine at Lonza’s mammalian manufacturing facility in Portsmouth, New Hampshire. Biologic medicines that

RST-001 is being developed as a first-in-class gene therapy application of optogenetics designed to restore vision to those affected by RP. Optogenetics refers to means of conferring light

The approval is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the US. The

According to the preliminary human and animal studies, Glassia may be able to treat and reduce the severity of GVHD, a life threatening complication of allogeneic stem cell

The company said that the cohort expansion comes after the initial stage of the trial confirmed that the maximum tolerated dose (MTD) of ME-344 in combination with topotecan

In addition to significantly strengthening the company’s balance sheet, Relmada’s CEO, Sergio Traversa, says the cash will help with its ambitious development strategy, "These funds enhance our flexibility